EP0776335A4 - Regulatable elimination of gene expression, gene product function and engineered host cells - Google Patents

Regulatable elimination of gene expression, gene product function and engineered host cells

Info

Publication number
EP0776335A4
EP0776335A4 EP95930868A EP95930868A EP0776335A4 EP 0776335 A4 EP0776335 A4 EP 0776335A4 EP 95930868 A EP95930868 A EP 95930868A EP 95930868 A EP95930868 A EP 95930868A EP 0776335 A4 EP0776335 A4 EP 0776335A4
Authority
EP
European Patent Office
Prior art keywords
regulatable
elimination
host cells
engineered host
product function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95930868A
Other languages
German (de)
French (fr)
Other versions
EP0776335A1 (en
Inventor
Joan S Brugge
Gerald R Crabtree
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Gene Therapeutics Inc
Original Assignee
Ariad Gene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/292,597 external-priority patent/US5834266A/en
Application filed by Ariad Gene Therapeutics Inc filed Critical Ariad Gene Therapeutics Inc
Publication of EP0776335A1 publication Critical patent/EP0776335A1/en
Publication of EP0776335A4 publication Critical patent/EP0776335A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP95930868A 1994-08-18 1995-08-18 Regulatable elimination of gene expression, gene product function and engineered host cells Withdrawn EP0776335A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US292595 1981-08-13
US29259594A 1994-08-18 1994-08-18
US29259694A 1994-08-18 1994-08-18
US08/292,597 US5834266A (en) 1993-02-12 1994-08-18 Regulated apoptosis
US292597 1994-08-18
US292596 1994-08-18
PCT/US1995/010591 WO1996006111A1 (en) 1994-08-18 1995-08-18 Regulatable elimination of gene expression, gene product function and engineered host cells

Publications (2)

Publication Number Publication Date
EP0776335A1 EP0776335A1 (en) 1997-06-04
EP0776335A4 true EP0776335A4 (en) 1999-09-15

Family

ID=27404137

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95930868A Withdrawn EP0776335A4 (en) 1994-08-18 1995-08-18 Regulatable elimination of gene expression, gene product function and engineered host cells

Country Status (5)

Country Link
EP (1) EP0776335A4 (en)
JP (1) JPH10507624A (en)
AU (1) AU3409295A (en)
CA (1) CA2197242A1 (en)
WO (1) WO1996006111A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233441T2 (en) 1991-04-26 2005-10-13 Osaka Bioscience Institute, Suita Human cell surface antigen encoding DNA
JPH11511643A (en) * 1994-10-25 1999-10-12 ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニア・ユニバーシティ Conditional transformation of genetically engineered cells
KR19990022651A (en) * 1995-06-07 1999-03-25 데이비드 엘. 버스테인 Rapamycin-Based Control of Biological Events
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
ES2183166T3 (en) * 1996-04-26 2003-03-16 Massachusetts Inst Technology TRIAL TEST FOR HYBRID TRIPLE.
US5858990A (en) * 1997-03-04 1999-01-12 St. Elizabeth's Medical Center Fas ligand compositions for treatment of proliferative disorders
AU6692298A (en) * 1997-03-07 1998-09-22 Ariad Gene Therapeutics, Inc. New applications of gene therapy technology
US6153383A (en) * 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
US6303848B1 (en) 1998-01-16 2001-10-16 Large Scale Biology Corporation Method for conferring herbicide, pest, or disease resistance in plant hosts
US6426185B1 (en) 1998-01-16 2002-07-30 Large Scale Biology Corporation Method of compiling a functional gene profile in a plant by transfecting a nucleic acid sequence of a donor plant into a different host plant in an anti-sense orientation
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
CA2330611A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
AU2044001A (en) * 1999-11-19 2001-05-30 Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
AUPR879701A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
CA2559791A1 (en) * 2003-07-08 2005-01-20 Axiogenesis Ag Secreted proteins as markers for cell differentiation
WO2008097875A1 (en) * 2007-02-08 2008-08-14 Neurologix, Inc. Novel methods for treating neurodegenerative disorders
US20120020885A1 (en) * 2010-07-26 2012-01-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware MHC-Less cells
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0425004A2 (en) * 1989-10-03 1991-05-02 Aveve N.V. Genetic manipulations with recombinant DNA comprising sequences derived from RNA virus
WO1993014768A1 (en) * 1992-01-27 1993-08-05 The Trustees Of The University Of Pennsylvania Methods and compositions for neutralizing intracellular nucleic acid-binding protein biological activity in a cell, including methods and compositions useful to regulate gene function
WO1994018317A1 (en) * 1993-02-12 1994-08-18 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293460C (en) * 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0425004A2 (en) * 1989-10-03 1991-05-02 Aveve N.V. Genetic manipulations with recombinant DNA comprising sequences derived from RNA virus
WO1993014768A1 (en) * 1992-01-27 1993-08-05 The Trustees Of The University Of Pennsylvania Methods and compositions for neutralizing intracellular nucleic acid-binding protein biological activity in a cell, including methods and compositions useful to regulate gene function
WO1994018317A1 (en) * 1993-02-12 1994-08-18 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO9606111A1 *
ZHAO, J.J. ET AL.: "Generating loss-of-function phenotypes of the fushi tarazu gene with a targeted ribozyme in Drosophila.", NATURE, vol. 365, 30 September 1993 (1993-09-30), pages 448 - 451, XP002108426 *

Also Published As

Publication number Publication date
AU3409295A (en) 1996-03-14
JPH10507624A (en) 1998-07-28
WO1996006111A1 (en) 1996-02-29
EP0776335A1 (en) 1997-06-04
CA2197242A1 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
EP0776335A4 (en) Regulatable elimination of gene expression, gene product function and engineered host cells
AU4053699A (en) Novel human genes and gene expression products
AU2095599A (en) Human genes and gene expression products i
AU4187499A (en) Human genes and gene expression products v
AU6360298A (en) Treated clay product, methods of making and using and products therefrom
AU6069300A (en) Novel human genes and gene expression products
HUT47972A (en) Halogen-aryl-nitriles degrading gene, process for its application and cells comprising same
PL316875A1 (en) Rps2 gene and applications thereof
AU5099599A (en) Bio-reaction process and product
AU5730896A (en) Fucosyltransferase genes and uses thereof
AU5700094A (en) Modified cutinases, dna, vector and host
AU4525696A (en) Novel retinoid-associated response elements, and related products
AU3648697A (en) Thermostable mutl genes and proteins and uses therefor
AU4911496A (en) Multiple component rna catalysts and uses thereof
AU4540196A (en) Alkylene oxide catalyst and process
HUT66831A (en) Novel invertase gene(s) and uses thereof
AU2861695A (en) Mn gene and protein
AU1607795A (en) Card-carrying sheets, process of making and method of using the same
AU2682495A (en) Novel transferase and amylase, process for producing the enzymes,use thereof, and gene coding for the same
AU4803997A (en) Polymorphisms and new genes in the region of the human hemochromatosis gene
AU7180298A (en) Nucleic acid encoding schwannominbinding-proteins and products related th ereto
AU6819194A (en) Isolated dna elements that direct pistil-specific and anther-specific gene expression and methods of using same
GB9511439D0 (en) Gene product and method
AU8396198A (en) Axin gene and uses thereof
GB9424661D0 (en) Enzymes, microorganisms and their use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970313

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT CH DE FR GB LI SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 6C 12N 15/00 A, 6C 07K 14/00 B, 6C 07H 21/00 B, 6C 12N 5/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 19990730

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT CH DE FR GB LI SE

17Q First examination report despatched

Effective date: 20010705

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020116